Niveditha Pinnamaneni1, Linda Moy2, Yiming Gao1, Amy N Melsaether2, James S Babb1, Hildegard K Toth1, Samantha L Heller3. 1. Laura and Isaac Perlmutter Center for Biomedical Imaging, Department of Radiology, New York University School of Medicine, 160 East 34th Street, 3rd Floor, New York, NY 10016. 2. Laura and Isaac Perlmutter Center for Biomedical Imaging, Department of Radiology, New York University School of Medicine, 160 East 34th Street, 3rd Floor, New York, NY 10016; Department of Radiology, Center for Advanced Imaging Innovation and Research (CAI(2)R), New York University School of Medicine, New York, New York. 3. Laura and Isaac Perlmutter Center for Biomedical Imaging, Department of Radiology, New York University School of Medicine, 160 East 34th Street, 3rd Floor, New York, NY 10016. Electronic address: Samantha.Heller@nyumc.org.
Abstract
RATIONALE AND OBJECTIVE: The objective of this study was to evaluate breast lesion outcomes in patients after canceled MRI-guided breast biopsy due to lesion nonvisualization. MATERIALS AND METHODS: Electronic medical records (January 2007-December 2014) were searched for patients with canceled magnetic resonance imaging (MRI)-guided breast biopsies due to lesion nonvisualization. A total of 1403 MRI-detected lesions were scheduled for MRI-guided biopsy and 89 were canceled because of nonvisualization. Imaging studies and medical records were reviewed for patient demographics, lesion characteristics, and subsequent malignancy. Patients without adequate MRI follow-up imaging were excluded. Statistical analysis was employed to determine if patient demographics or lesion characteristics were predictive of lesion resolution or lesion biopsy after subsequent follow-up. RESULTS: Eighty-nine (6.3% [89/1403]; 95% confidence interval, 5.2%-7.7%) biopsies in 89 women were canceled because of nonvisualization. Follow-up MRIs greater than 5.5 months were available for 60.7% (54/89) of women. In 74.1% (40/54) of these patients, the lesions completely resolved on follow-up. In 25.9% (14/54) of the patients, the lesion persisted on follow-up; 42.9% (6/14) of these patients underwent biopsy. One case (1.9% [1/54]) yielded ductal carcinoma in situ with microinvasion at the 6-month follow-up. No patient demographics or lesion features were associated with lesion resolution or lesion biopsy. CONCLUSIONS: The majority of canceled MRI-guided biopsy lesions resolved on later follow-up; however, because of the small possibility of a missed malignancy, follow-up MRI imaging at 6 months is recommended.
RATIONALE AND OBJECTIVE: The objective of this study was to evaluate breast lesion outcomes in patients after canceled MRI-guided breast biopsy due to lesion nonvisualization. MATERIALS AND METHODS: Electronic medical records (January 2007-December 2014) were searched for patients with canceled magnetic resonance imaging (MRI)-guided breast biopsies due to lesion nonvisualization. A total of 1403 MRI-detected lesions were scheduled for MRI-guided biopsy and 89 were canceled because of nonvisualization. Imaging studies and medical records were reviewed for patient demographics, lesion characteristics, and subsequent malignancy. Patients without adequate MRI follow-up imaging were excluded. Statistical analysis was employed to determine if patient demographics or lesion characteristics were predictive of lesion resolution or lesion biopsy after subsequent follow-up. RESULTS: Eighty-nine (6.3% [89/1403]; 95% confidence interval, 5.2%-7.7%) biopsies in 89 women were canceled because of nonvisualization. Follow-up MRIs greater than 5.5 months were available for 60.7% (54/89) of women. In 74.1% (40/54) of these patients, the lesions completely resolved on follow-up. In 25.9% (14/54) of the patients, the lesion persisted on follow-up; 42.9% (6/14) of these patients underwent biopsy. One case (1.9% [1/54]) yielded ductal carcinoma in situ with microinvasion at the 6-month follow-up. No patient demographics or lesion features were associated with lesion resolution or lesion biopsy. CONCLUSIONS: The majority of canceled MRI-guided biopsy lesions resolved on later follow-up; however, because of the small possibility of a missed malignancy, follow-up MRI imaging at 6 months is recommended.
Authors: Kelly S Myers; Eniola T Oluyemi; Lisa A Mullen; Babita Panigrahi; Philip A Di Carlo; Derek L Nguyen; Emily B Ambinder Journal: J Breast Imaging Date: 2022-06-20
Authors: Beatriz E Adrada; Mary S Guirguis; Tuan Hoang; David A Spak; Gaiane M Rauch; Tanya W Moseley Journal: Radiographics Date: 2022-02-04 Impact factor: 5.333